Clinical Edge Journal Scan

Genetic mutation burden can predict prognosis for myelodysplastic syndrome


 

Key clinical point: A mutation load of the gene U2AF1 (VAF > 40%) was an independent indicator of lower 1-year survival in adults with myelodysplastic syndrome.

Major finding : Myelodysplastic syndrome patients with a higher mutation load of U2AF1 (VAF > 40%) had a significantly lower 1-year survival rate compared to those with a mutation load of VAF 40 or lower (46.1% and 80.5%, respectively, P= 0.027).

Study details : The data come from genetic analyses of 234 myelodysplastic syndrome patients aged 17 to 86 years; a total of 51 patients had an U2AF1 mutation at 52 mutation sites.

Disclosures: The study was supported by the National Natural Science Foundation of China; Henan Natural Science Foundation of China and by the Henan Medical Science and Technology Research Project, Key Scientific Research Project of Henan Provincial Education Department. The researchers had no financial conflicts to disclose.

Source: Wang H et al. Sci Rep. 2020 Oct 29. doi: 10.1038/s41598-020-74744-z.

Recommended Reading

Gene mutations may predict risk of vascular events in MDS
Federal Practitioner
Myelodysplastic Syndrome Journal Scans: November 2020
Federal Practitioner
In MDS, transplant ups survival in elderly and may be reimbursed
Federal Practitioner
Extended virus shedding after COVID-19 in some patients with cancer
Federal Practitioner
Synthetic retinoid shows potential for myeloid malignancies
Federal Practitioner
Monthly azacitidine injections reduce relapse in acute myeloid leukemia and myelodysplastic syndrome
Federal Practitioner
Food supplements improve mitochondrial respiration in myelodysplastic syndrome
Federal Practitioner
Imetelstat curbs need for blood transfusions in myelodysplastic syndrome
Federal Practitioner
Azacitidine shows safety but lacks effectiveness for relapse reduction in myelodysplastic syndrome and acute myeloid leukemia
Federal Practitioner
Novel gene fusions surface more often in acute myeloid leukemia vs. myelodysplastic syndrome
Federal Practitioner